Skeletal responses to romosozumab after 12 months of denosumab-Reference-Cited by-同舟云学术

Skeletal responses to romosozumab after 12 months of denosumab

Published:2021-06-03 Issue:7 Volume:5 Page:
ISSN:2473-4039
Container-title:JBMR Plus
language:en
Short-container-title:JBMR Plus

Author:

McClung Michael R.¹²^ORCID,Bolognese Michael A.³,Brown Jacques P.⁴,Reginster Jean‐Yves⁵⁶,Langdahl Bente L.⁷^ORCID,Shi Yifei⁸,Timoshanko Jen⁹,Libanati Cesar⁹^ORCID,Chines Arkadi⁸,Oates Mary K.⁸

Affiliation:

1. Oregon Osteoporosis Center Portland Oregon USA

2. Mary MacKillop Institute for Health Research Australian Catholic University Melbourne Victoria Australia

3. Bethesda Health Research Center Bethesda Maryland USA

4. Laval University and CHU de Quebec (CHUL) Research Centre Quebec City Quebec Canada

5. University of Liege Liege Belgium

6. King Saud University Riyadh Saudi Arabia

7. Aarhus University Hospital Aarhus Denmark

8. Amgen Inc. Thousand Oaks California USA

9. UCB Pharma Brussels Belgium

Publisher

Wiley

Subject

Orthopedics and Sports Medicine,Endocrinology, Diabetes and Metabolism

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/jbm4.10512

Reference32 articles.

1. Osteoporosis

2. Risedronate Preserves Bone Architecture in Early Postmenopausal Women In 1 Year as Measured by Three-Dimensional Microcomputed Tomography

3. Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis

4. Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomised controlled trial

5. Bone‐Forming and Antiresorptive Effects of Romosozumab in Postmenopausal Women With Osteoporosis: Bone Histomorphometry and Microcomputed Tomography Analysis After 2 and 12 Months of Treatment

Cited by 35 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Progression of multiple vertebral fractures after denosumab discontinuation under treatment with romosozumab. A case-report;Joint Bone Spine;2024-09

2. Author response to: OSIN-D-24–00849 Comment on: A novel sequential treatment approach between denosumab and romosozumab in patients with severe osteoporosis;Osteoporosis International;2024-08-09

3. Goal-directed osteoporosis treatment: ASBMR/BHOF task force position statement 2024;Journal of Bone and Mineral Research;2024-07-29

4. Romosozumab versus parathyroid hormone receptor agonists: which osteoanabolic to choose and when?;European Journal of Endocrinology;2024-06-28

5. The effect of romosozumab on bone mineral density depending on prior treatment: a prospective, multicentre cohort study in Switzerland;Osteoporosis International;2024-06-26